We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

A Nanowire-based Liquid Biopsy Method for Detection of Tumors of the Central Nervous System

By LabMedica International staff writers
Posted on 30 Jun 2021
Print article
Image: Artist’s depiction of nanowire scaffolds for the screening of urinary microRNAs from patients with central nervous system tumors (Photo courtesy of Takao Yasui and Atsushi Natsume, Nagoya University)
Image: Artist’s depiction of nanowire scaffolds for the screening of urinary microRNAs from patients with central nervous system tumors (Photo courtesy of Takao Yasui and Atsushi Natsume, Nagoya University)
Researchers have developed a sterilizable nanowire-based device that can efficiently extract urinary microRNAs (miRNAs) and used it as the basis of a liquid biopsy method to detect tumors of the central nervous system (CNS).

MiRNAs comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia and cardiovascular conditions.

Liquid biopsy methods to detect circulating nucleic acids from CNS tumors have not been developed due to the presence of the blood–brain barrier, which restricts molecular exchange between the tumor and the general circulation. Furthermore, collection of urinary biomarkers is difficult, and urine-based liquid biopsies have not been fully studied.

To solve these problems, investigators at Nagoya University (Japan) developed a mass-producible and sterilizable nanowire-based device capable of efficiently extracting urinary microRNAs. The device contained approximately 100 million zinc oxide nanowires and was suitable for actual medical use.

The investigators used the device as basis for a liquid biopsy method to analyze urinary microRNA expression profiles from 119 patients with CNS tumors and 100 control individuals. Results showed that this approach could distinguish the patients from control individuals at a sensitivity of 100% and a specificity of 97%, regardless of the malignancy and size of tumors.

"Urine can be collected easily without putting a burden on the human body," said senior author Dr. Atsushi Natsume, associate professor of neurosurgery at Nagoya University. "Urine-based liquid biopsy had not been fully investigated for patients with brain tumors, because none of the conventional methodologies can extract microRNAs from urine efficiently in terms of varieties and quantities. So, we decided to develop a device capable of doing it. In the future, by a combination of artificial intelligence and telemedicine, people will be able to know the presence of cancer, whereas doctors will be able to know the status of cancer patients just with a small amount of their daily urine."

The nanowire miRNA extraction device was described in the April 1, 2021, issue of the journal ACS Applied Materials & Interfaces.

Related Links:
Nagoya University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more